Patient satisfaction with 6-month paliperidone palmitate versus other long-acting injectable antipsychotics

被引：0
|
作者：
Perez-Balaguer, A. [1 ]
Garcia del Castillo, I. [1 ]
Gomez-Esteban, B. [1 ]
Vicente-Burguillo, M. [1 ]
Vizcaino-Herrezuelo, H. [2 ]
Castelao-Almodovar, S. [2 ]
Arce de la Riva, A. [2 ]
Neira-Serrano, F. [3 ]
机构：
[1] El Escorial Hosp, Psychiat, Madrid, Spain
[2] Puerta Hierro Univ Hosp, Psychiat, Madrid, Spain
[3] Francisco Vitoria Univ, Stat, Madrid, Spain
来源：
EUROPEAN PSYCHIATRY | 2024年 / 67卷
关键词：
D O I：
10.1192/j.eurpsy.2024.1509
中图分类号：
R749 [精神病学];
学科分类号：
100205 ;
摘要：
EPV0909
引用
收藏
页码：S726 / S726
页数：1
相关论文
共 50 条
  • [31] In vitro and in vivo characterization of Invega Sustenna® (paliperidone palmitate long-acting injectable suspension)
    Li, Ji
    Rodriguez, Antonela
    Wang, Kaikai
    Olsen, Karl
    Wang, Yan
    Schwendeman, Anna
    EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2025, 207
  • [32] Paliperidone Palmitate versus Risperidone Long-Acting Injectable in Patients with Schizophrenia: A Meta-Analysis of Efficacy and Safety
    Zhao, Mingjun
    Qin, Bin
    Mao, Yage
    Zhang, Yang
    Zhao, Ruisheng
    Wang, Aiqin
    Wang, Hailing
    Zhao, Jianting
    Wang, Changhong
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2023, 19 : 749 - 757
  • [33] Modeling the budget impact of long-acting injectable paliperidone palmitate in the treatment of schizophrenia in Japan
    Mahlich, Jorg
    Nishi, Masamichi
    Saito, Yoshimichi
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2015, 7 : 267 - 272
  • [34] EVALUATION OF PALIPERIDONE PALMITATE LONG-ACTING INJECTABLE THERAPY BY DURATION OF ILLNESS IN PATIENTS WITH SCHIZOPHRENIA
    Brown, B.
    Turkoz, I.
    Mancevski, B.
    Mathews, M.
    Reeve-Parker, K.
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 2017, 51 : 161 - 161
  • [35] A stitch in time: 3-monthly long-acting injectable paliperidone palmitate in schizophrenia
    Taylor, Mark
    Huang, Hannah Chu-Han
    THERAPEUTIC ADVANCES IN PSYCHOPHARMACOLOGY, 2017, 7 (10) : 231 - 233
  • [36] Cost-Effectiveness of Long-Acting Injectable Paliperidone Palmitate Versus Haloperidol Decanoate in Maintenance Treatment of Schizophrenia
    Rosenheck, Robert A.
    Leslie, Douglas L.
    Sint, Kyaw J.
    Lin, Haiqun
    Li, Yue
    McEvoy, Joseph P.
    Byerly, Matthew J.
    Hamer, Robert M.
    Swartz, Marvin S.
    Stroup, T. Scott
    PSYCHIATRIC SERVICES, 2016, 67 (10) : 1123 - 1129
  • [37] Evaluation of Paliperidone Palmitate Long-Acting Injectable Therapy by Duration of Illness in Patients With Schizophrenia
    Brown, Brianne
    Turkoz, Ibrahim
    Mancevski, Branislav
    Mathews, Maju
    BIOLOGICAL PSYCHIATRY, 2016, 79 (09) : 212S - 212S
  • [38] Evaluation of Paliperidone Palmitate Long-Acting Injectable Therapy by Duration of Illness in Patients With Schizophrenia
    Brown, Brianne
    Turkoz, Ibrahim
    Mancevski, Branislav
    Mathews, Maju
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2016, 19 : 198 - 198
  • [39] Bilateral Pretibial Edema Associated with Paliperidone Palmitate Long-acting Injectable: A Case Report
    Cicek, Erdinc
    Cicek, Ismet Esra
    Uguz, Faruk
    CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE, 2017, 15 (02) : 184 - 186
  • [40] Cost minimization analysis comparing paliperidone palmitate with risperidone long-acting injectable in Spain
    Quintero, I.
    Gonzalez, B.
    Garcia, I.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2012, 15 : 50 - 50
12345